PALO ALTO, Calif.—Affymax Inc. announced Aug. 10 that it has received a $10 million development milestone payment from Takeda Pharmaceutical Company due to the FDA’s acceptance and filing of a New Drug Application for the anemia drug peginesatide.
The payment is part of the companies' exclusive global agreement to develop and commercialize peginesatide (formerly known as Hematide), Affymax's investigational drug for the treatment of anemia in chronic renal failure patients.
If approved, peginesatide will be the first once-monthly erythropoiesis stimulating agent (ESA) available for the treatment of anemia associated with CKD patients on dialysis in the United States, according to Affymax.
Affymax and Takeda Pharmaceutical North America are collaborating on the development of peginesatide and plan to co-commercialize the product if approved in the United States. The product, upon approval, will be commercialized outside the United States by Takeda.
